KMTS Stock Forecast & Price Target

Kestra Medical Techs is attractive fundamentally because it is delivering rapid commercial traction, with F1Q27 sales of $31.0M, up 60% year over year and ahead of consensus, while management raised FY27 revenue guidance to $141M, implying 48% growth. The company is also showing improving unit economics, as gross margin expanded to 56.5% from 45.7% in the prior-year period, marking the 11th consecutive quarter of sequential expansion, supported by a higher mix of in-network patients, better revenue cycle management, and share gains in a market where it estimates about 15% U.S. share. With approximately $320M of liquidity, a growing patent portfolio, and evidence from ACE-PAS and prior studies of strong compliance and low inappropriate shock rates, the business appears positioned to keep scaling while investing in R&D and commercial infrastructure.

Kestra Medical Techs is facing a fundamentally challenging market because WCD adoption depends on subjective patient selection, uncertain mortality benefit, and compliance requiring wear time above 22 hours per day, all of which make outcomes hard to predict and limit broad uptake. The landmark VEST trial in 2018 failed to meet its primary endpoint, with arrhythmic death at 1.6% in the device arm versus 2.4% in control, reinforcing doubts about clear clinical benefit and cost-effectiveness. Although Kestra has quickly captured about 12% U.S. share, it still competes against ZOLL in a $1.25B market while trading at about 7.4x forward P/S, a steep premium that leaves little room for execution missteps.